Region Skane

• Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) with Atorvastatin (ATORGO) Pending
  2023-504654-35-00 Phase II 1 country ATORVASTATIN
• The therapeutic potential of psilocybin in anorexia nervosa in young adults Pending
  2024-515163-63-00 Phase II 1 country DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL
• Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on… Pending
  2024-518191-31-00 Phase IV 1 country RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-…
• Contrast Strategy In Fenestrated EndoVascular Aneurysm Repair Randomized Control Trial Pending
  2025-521795-58-00 Phase III/IV 2 countries IODIXANOL; IOHEXOL; IOMEPROL
• IRONGIRLS-PILOT: Feasibility of Alternate-Day Iron Supplementation in Adolescent Girls Pending
  2025-522498-12-00 Phase IV 1 country FERROUS SULFATE
• Comparing intraoperative indocyanine green fluorescence imaging with standard clinical assessment for flap perfusion in head and neck recons… Pending
  2025-524710-29-00 Phase IV 1 country INDOCYANINE GREEN
• Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy Pending
  2025-524722-17-00 Phase IV 1 country MAVACAMTEN
• Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial Pending
  2026-525838-32-00 Phase IV 1 country MORPHINE HYDROCHLORIDE; SODIUM CHLORIDE
• Neoadjuvant and postoperative treatment with dabrafenib and trametinib for papillary craniopharyngioma Recruiting
  2024-517611-67-00 Phase II 1 country
• HYPER-trial Hyperemic mYocardial Perfusion by adEnosine at diffeRent doses Recruiting
  2023-505248-20-00 Phase IV 1 country ADENOSINE; GADOTERIC ACID
• PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma Recruiting
  2022-501993-21-00 Phase II 3 countries PEMIGATINIB; RETIFANLIMAB
• COMeBAC- COMparison between Bensypenicillin And Cloxacillin treatment in PSSA Recruiting
  2023-506860-15-00 Phase IV 1 country BENZYLPENICILLIN SODIUM; CLOXACILLIN
• Alternative antibiotics to multidrug-resistant UTIs Recruiting
  2024-513294-41-00 Phase IV 1 country AMOXICILLIN, CLAVULANIC ACID; CIPROFLOXACIN; ERTAPENEM; PIVMECILLINAM HYDROCHLOR…
• Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An open-label, multi-center, randomized phase III trial comparing safety a… Recruiting
  2023-508572-11-00 Phase III 1 country LUTETIUM (177LU) EDOTREOTIDE
• ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study Recruiting
  2024-518172-31-01 Phase III 1 country
• Accelerated treatment of infectious endocarditis Recruiting
  2023-507652-76-00 Phase III/IV 1 country AMPICILLIN; BENZYLPENICILLIN SODIUM; CEFOTAXIME; CEFTRIAXONE SODIUM; CLOXACILLIN…
• Positron emission tomography (PET) of patients with brain injury and athletes with concussion symptoms - Descriptive study of the tau tracer… Recruiting
  2024-517048-67-00 Phase II 1 country 2-(6-[18F]FLUORO-PYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B:3',4'-D]PYRROLE
• Treatment of Graves´ ophthalmopathy with diclofenak or simvastatin Recruiting
  2024-517833-42-00 Phase II/III 1 country
• Stopping anti-TNF treatment in Crohn's and Colitis patients in remission Recruiting
  2024-513299-17-00 Phase IV 1 country ADALIMUMAB; INFLIXIMAB
• The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders Recruiting
  2024-511842-38-00 Phase II 1 country 2-(6-[18F]FLUORO-PYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B:3',4'-D]PYRROLE; FLUTEMETAMOL (…
• A trial to determine the safety and tolerability of transplanted stem cellderived dopamine neurons to the brains of individuals with Parkins… Ended
  2024-511237-35-00 Phase I (FiH) 1 country
• Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended
  2023-509864-96-00 Phase II 4 countries
• Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial) Ended
  2023-504945-30-00 Phase III 1 country GEMCITABINE; MITOMYCIN
• POLAR BEAR Ended
  2022-502887-19-00 Phase III 6 countries POLATUZUMAB VEDOTIN

Showing 1–24 of 34 trials